Magle PharmaCept, a part of Magle Group, announces a strategic partnership with Pancreatic Cancer Europe (PCE), Pancreatic Cancer Europe is a European multi-stakeholder platform which aims at bringing together experts from all over Europe including academics, physicians, politicians, patient groups and journalists with a common interest and willingness to improve care for patients with pancreatic […]
We are excited to share the results of the recent SmartPAN post-market trial for elective pancreatic resections. The study assessed SmartPAN’s usability, safety, and its ability to detect intraoperative pancreatic leakage. Visualization of Intraoperative Pancreatic Leakage (ViP): The IDEAL Stage I First-in-human, Single-arm Clinical Pilot Trial of SmartPAN Key Insights For further details and to […]
From February 27th to March 1st, 2025 it’s all about the Pancreatic Surgery! Magle PharmaCept team will be participating at 44th Annual Meeting of The German Pancreatic Club in Heidelberg. Looking forward to meeting you at our symposium “ Progress and Challenges of Modern Pancreatic Surgery “ Read more Welcome to our booth for hands-on […]
Magle PharmaCept as a part of Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) announces the publication of the final results of the prospective HepaStar trial, a multicenter observational trial evaluating the safety and effectiveness of EmboCept® S DSM 50 µm in the treatment of unresectable hepatocellular carcinoma (HCC). Hepatocellular carcinoma (HCC) is the […]
Magle Group is proud to announce that its approved the initiation of a multi-centre clinical trial to explore the use of EmboCept® S in Genicular Artery Embolisation (GAE), a minimally-invasive procedure aimed at delivering immediate and long-term pain relief for patients suffering from osteoarthritis (OA) of the knee. This innovative treatment, performed by interventional radiologists […]
Our team actively participated in the congress, diving deep into arterial interventions. Over the past few days, Helena Ossmer Thedius, Chief Marketing and Innovation Officer at Magle Group, and Franziska Sahm, Dr. Medical Affairs Manager at Magle PharmaCept, have attended highly informative meetings at CIRSE 2024. The congress provided an opportunity for participants to gain […]
Magle PharmaCept, a subsidiary of Magle Group, is pleased to announce the extension of its distribution agreement with its key distributor in the wound care field. The expanded agreement now includes strategic European territories, enhancing our reach and reinforcing our commitment to providing innovative wound care solutions across the region. AXXO® Woundgel, the brand owned […]
At Magle Group, our unwavering commitment to excellence drives us forward. Recently Magle Chemoswed announced the partnership with Dara Pharmaceutical Equipment, resulting in the acquisition of a state-of-the-art automated syringe filling and closing line. Our aspiration is to provide high quality healthcare innovations while constantly expanding our capabilities. With this remarkable addition, we’re taking a […]
At Magle PharmaCept, we are excited to announce our participation in the European Conference on Embolotherapy ET2024 Congress, in Vienna, where we gain Insights and focus on embolization in various areas. Attending sessions and connecting with partners and healthcare professionals broaden our understanding of user needs and create value for patients. collaboration between different specialties […]
Magle Group, through its subsidiary Magle PharmaCept, is excited to announce the appointment of a new distributor for SmartPAN® in Singapore. This strategic partnership represents a pivotal step in our efforts to introduce SmartPAN® to the Asian market, underlining our commitment to improving pancreatic surgery outcomes globally. Regulatory approval for SmartPAN® in Singapore is currently […]
